Tesamorelin

What is Tesamorelin?#

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a trans-3-hexenoic acid group attached to the N-terminal tyrosine residue. This lipophilic modification distinguishes tesamorelin from native GHRH (1-44) and confers improved stability against enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), the primary enzyme responsible for GHRH inactivation in the circulation. The result is a more potent and longer-acting GHRH analog that stimulates growth hormone (GH) release from anterior pituitary somatotroph cells while preserving the pulsatile, physiological pattern of GH secretion.

Tesamorelin was developed by Theratechnologies Inc. and is marketed under the brand name Egrifta (tesamorelin for injection). It received FDA approval in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It was the first and remains the only FDA-approved treatment specifically indicated for HIV-associated lipodystrophy, a condition characterized by abnormal accumulation of visceral adipose tissue (VAT) that occurs as a metabolic complication of antiretroviral therapy and HIV infection itself.

The drug is administered as a once-daily subcutaneous injection at a dose of 2 mg. Unlike exogenous GH replacement, which bypasses the hypothalamic-pituitary axis and delivers supraphysiological GH levels, tesamorelin works by stimulating the patient's own pituitary gland to produce and release GH in a regulated manner. This physiological approach preserves the normal feedback mechanisms involving insulin-like growth factor-1 (IGF-1) and somatostatin, theoretically reducing the risk of adverse effects associated with GH excess.

In 2020, Theratechnologies received FDA approval for Egrifta SV, a reformulated version requiring smaller injection volumes and improved ease of use. The clinical pharmacology and efficacy profile remain equivalent to the original formulation.

Mechanism of Action#

GHRH Receptor Activation#

Tesamorelin binds to and activates the GHRH receptor (GHRHR), a G-protein coupled receptor expressed primarily on somatotroph cells of the anterior pituitary gland. Upon receptor engagement, the Gs-alpha subunit activates adenylate cyclase, leading to increased intracellular cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream targets including the transcription factor CREB (cAMP response element-binding protein), ultimately driving transcription of the GH gene and promoting GH synthesis and secretion.

The trans-3-hexenoic acid modification at the N-terminus of tesamorelin does not alter receptor binding specificity but provides steric protection against DPP-IV cleavage at the Tyr1-Ala2 bond, which is the primary site of native GHRH degradation. This modification extends the effective half-life of tesamorelin compared to native GHRH, allowing once-daily dosing to achieve therapeutically meaningful GH stimulation.

Physiological GH Pulsatility#

A distinguishing pharmacological feature of tesamorelin is that it stimulates GH release in a pulsatile fashion that closely mimics the natural pattern of GH secretion. In healthy physiology, GH is released in episodic pulses governed by the interplay between hypothalamic GHRH (stimulatory) and somatostatin (inhibitory). By acting at the level of the pituitary GHRH receptor, tesamorelin respects this regulatory architecture. GH release occurs in augmented pulses rather than continuous elevation, and the somatostatin-mediated feedback mechanisms remain intact.

This is in contrast to direct GH injection, which produces an immediate, non-physiological peak followed by decline, bypassing normal regulatory control. The pulsatile stimulation pattern is considered clinically advantageous because it maintains sensitivity of GH receptors in target tissues and avoids the tachyphylaxis and supraphysiological IGF-1 levels more commonly associated with exogenous GH.

Downstream Metabolic Effects#

The GH released in response to tesamorelin exerts its metabolic effects both directly and through hepatic production of IGF-1. In adipose tissue, GH promotes lipolysis by activating hormone-sensitive lipase (HSL) and inhibiting lipoprotein lipase (LPL), resulting in mobilization of stored triglycerides and reduction of adipocyte size. Visceral adipose tissue is particularly responsive to GH-mediated lipolysis due to its high density of GH receptors and beta-adrenergic receptors, which may explain the preferential reduction of visceral fat observed with tesamorelin treatment.

GH also has anabolic effects in skeletal muscle and other lean tissues, mediated largely through IGF-1 signaling via the IGF-1 receptor and downstream PI3K/Akt/mTOR pathways. In clinical studies of tesamorelin, increases in IGF-1 levels were observed but remained within the age-adjusted normal range for the majority of patients, consistent with the physiological stimulation approach.

Additionally, GH influences hepatic lipid metabolism by reducing hepatic de novo lipogenesis and enhancing very low-density lipoprotein (VLDL) clearance. These effects may contribute to the improvements in lipid parameters observed in tesamorelin clinical trials, including reductions in triglycerides and total cholesterol in some study populations.

Therapeutic Applications and Clinical Evidence#

HIV-Associated Lipodystrophy (Approved Indication)#

The pivotal clinical evidence for tesamorelin comes from two Phase 3, randomized, double-blind, placebo-controlled trials that established its efficacy for HIV-associated lipodystrophy.

In the first pivotal trial, 412 HIV-infected patients with excess abdominal fat (waist circumference greater than the 95th percentile for age and sex or CT-confirmed visceral adiposity) were randomized to tesamorelin 2 mg or placebo for 26 weeks. Tesamorelin produced a mean reduction in trunk fat of 15.2% from baseline, compared to a 5.0% increase in the placebo group (treatment difference -20.2%, p<0.0001). CT imaging demonstrated a mean reduction in visceral adipose tissue of approximately 15.4% in the tesamorelin group versus a 5.2% increase with placebo.

The second pivotal trial (n=404) confirmed these findings, with tesamorelin reducing VAT by approximately 14% compared to baseline while placebo-treated patients showed no significant change. In both trials, the VAT reduction was evident by week 13 and maintained through week 26. Improvements in patient-reported body image and trunk fat distribution were also statistically significant.

Notably, an extension study examining the durability of response found that discontinuation of tesamorelin led to reaccumulation of visceral fat, indicating that ongoing treatment is necessary to maintain the metabolic benefit. In patients who continued treatment for 52 weeks, VAT reductions were maintained or further improved.

Secondary metabolic endpoints showed improvements in trunk-to-limb fat ratio and triglyceride levels in some analyses. Body weight remained largely stable, consistent with preferential loss of visceral fat rather than generalized weight loss. Subcutaneous adipose tissue was relatively preserved, an important consideration given that subcutaneous lipoatrophy is a separate and distressing feature of HIV-associated lipodystrophy.

Lipid Profile Improvements#

Across clinical trials, tesamorelin treatment was associated with improvements in several lipid parameters. Mean triglyceride levels decreased by approximately 50 mg/dL in tesamorelin-treated patients in some trial analyses, compared to minimal change with placebo. Non-HDL cholesterol showed trends toward improvement. However, the lipid effects were not uniformly significant across all trials and subgroup analyses, and tesamorelin is not approved for the treatment of dyslipidemia.

NASH and Hepatic Steatosis Research#

An area of active investigation is the potential role of tesamorelin in nonalcoholic steatohepatitis (NASH) and hepatic steatosis. GH deficiency and relative GH insufficiency have been implicated in the pathogenesis of hepatic fat accumulation, and restoring GH signaling through GHRH stimulation may address this pathophysiology.

A randomized, double-blind, placebo-controlled trial (the GILT trial) investigated tesamorelin in HIV-infected patients with hepatic steatosis (liver fat fraction greater than 5% by MRI). Treatment with tesamorelin 2 mg daily for 12 months resulted in a significant reduction in hepatic fat fraction (-37% relative change from baseline) compared to placebo (-10%, p<0.01). The proportion of patients achieving resolution of hepatic steatosis (liver fat below 5%) was significantly higher with tesamorelin (35%) than placebo (4%). Histological assessments in a subset of patients showed improvement in NAFLD activity scores and trends toward reduced fibrosis.

These hepatic findings are of particular interest because NASH has emerged as a leading cause of liver disease in the HIV-positive population, and no pharmacotherapy is specifically approved for NASH in this setting. Additional studies are underway to further characterize tesamorelin's effects on liver histology and to explore potential utility in non-HIV NASH populations.

Cognitive Function Research#

Emerging evidence suggests a relationship between GH/IGF-1 axis activity and cognitive function, particularly in aging populations. A small randomized trial investigated tesamorelin's effects on cognitive function in healthy older adults and found improvements in executive function and verbal memory compared to placebo over a 20-week treatment period. The cognitive benefits correlated with increases in IGF-1 levels, suggesting a possible mediating mechanism.

While these findings are preliminary, they have generated interest in the potential neuroprotective and cognitive-enhancing effects of physiological GH restoration. However, larger confirmatory trials with longer follow-up are necessary before any cognitive indications can be considered evidence-based.

Evidence Gaps and Limitations#

Population Specificity#

The FDA approval and the bulk of clinical evidence for tesamorelin are specific to HIV-infected patients with lipodystrophy. Whether the visceral fat reduction and metabolic benefits extend to other populations with visceral obesity or metabolic syndrome is not established by robust clinical trials. Extrapolation of efficacy to non-HIV populations requires caution given the unique pathophysiology of HIV-associated lipodystrophy, including the contributions of antiretroviral drugs, chronic inflammation, and immune dysregulation.

Reversibility of Effects#

The observation that visceral fat reaccumulates upon discontinuation of tesamorelin raises questions about the optimal duration of therapy and the long-term benefit-risk profile of indefinite treatment. There are limited long-term safety data beyond 52 weeks of continuous treatment, and the consequences of prolonged GH axis stimulation in the HIV-infected population, including potential effects on glucose metabolism and cancer risk, remain incompletely characterized.

Glucose Metabolism Concerns#

GH is a counter-regulatory hormone that opposes insulin action, and tesamorelin has been associated with modest increases in fasting glucose and HbA1c in some clinical trials. In the pivotal studies, the incidence of new-onset diabetes or glucose intolerance was numerically higher in tesamorelin-treated patients, though not statistically significant in individual trials. For patients with pre-existing insulin resistance, a common feature of HIV-associated metabolic disease, the potential for glucose dysregulation warrants monitoring.

IGF-1 Elevations and Cancer Risk#

While IGF-1 levels generally remained within the normal range during tesamorelin treatment, some patients experienced supranormal IGF-1 elevations. Given epidemiological associations between elevated IGF-1 and increased risk of certain malignancies, this is a theoretical concern, particularly in a population (HIV-infected individuals) with baseline elevated cancer risks. Long-term post-marketing surveillance studies examining cancer incidence in tesamorelin-treated patients have not been comprehensively reported.

Limited Comparative Data#

There are no head-to-head clinical trials comparing tesamorelin to other interventions for visceral adiposity, including lifestyle modification programs, GH replacement therapy, or other GH secretagogues. The relative efficacy and safety of tesamorelin compared to these alternatives remain undefined.

Hepatic and Cognitive Indications#

The NASH and cognitive function data, while scientifically compelling, derive from relatively small trials with limited follow-up. These applications remain investigational, and the evidence base is insufficient to support clinical use outside of the approved HIV lipodystrophy indication. The ongoing trials in these domains will be critical to determining whether tesamorelin offers clinically meaningful benefits in broader patient populations.

Cost and Access#

As a branded specialty pharmaceutical, tesamorelin carries a significant cost burden, which may limit access for patients who could benefit from treatment. Generic alternatives are not currently available, and the economic implications of indefinite therapy have not been formally evaluated through health economic analyses in most healthcare systems.

Key Research Findings#

Effects of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients with abdominal fat accumulation (Pivotal Trial 1), published in New England Journal of Medicine (Falutz J et al., 2007; PMID: 18057338):

• The study showed mean trunk fat reduction of 15.2% with tesamorelin vs. 5.0% increase with placebo
• The study demonstrated VAT reduction of of 15.4% by CT imaging

Tesamorelin for the treatment of trunk fat in HIV-infected patients (Pivotal Trial 2), published in Journal of Acquired Immune Deficiency Syndromes (Falutz J et al., 2010; PMID: 20101189):

• The study demonstrated VAT reduced by of 14% from baseline with tesamorelin

Tesamorelin reduces liver fat and hepatic steatosis in HIV-associated NAFLD (GILT Trial), published in Lancet HIV (Stanley TL et al., 2019; PMID: 31611038):

• The study showed hepatic fat fraction reduced by 37% relative change from baseline with tesamorelin vs. 10% with placebo
• The study demonstrated of tesamorelin patients achieved resolution of steatosis of 35% vs. 4% with placebo

Related Reading#

• Tesamorelin research studies and evidence
• Tesamorelin dosing protocols
• Tesamorelin side effects profile
• GHRP-2 research guide
• Hexarelin research guide